The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 192(2018) vom: 05. Juli, Seite 85-91
1. Verfasser: Sthoeger, Zev (VerfasserIn)
Weitere Verfasser: Sharabi, Amir, Asher, Ilan, Zinger, Heidy, Segal, Rafael, Shearer, Gene, Elkayam, Ori, Mozes, Edna
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Cytokines Immunomodulation of gene expression Indoleamine 2,3-dioxygenase (IDO) Primary Sjogren's syndrome (pSS) Tolerogenic peptide (hCDR1) Antibodies, Monoclonal FOXP3 protein, human Forkhead Transcription Factors Immunologic Factors mehr... Peptide Fragments Peptides Transforming Growth Factor beta edratide 38PLP07BKC
Beschreibung
Zusammenfassung:Copyright © 2018 Elsevier Inc. All rights reserved.
Primary Sjogren's syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands. We investigated whether the tolerogenic peptide, hCDR1, that ameliorates lupus manifestations would have beneficial effects on pSS as well. The in vitro effects of hCDR1 on gene expression of pro-inflammatory cytokines and regulatory molecules were tested in peripheral blood mononuclear cells (PBMC) of 16 pSS patients. hCDR1, but not a control peptide, significantly reduced gene expression of IL-1β, TNF-α, MX-1 and BlyS and up-regulated immunosuppressive (TGF-β, FOXP3) molecules in PBMC of pSS patients. hCDR1 did not affect gene expression in patients with rheumatoid arthritis and anti-phospholipid syndrome. Further, hCDR1 up-regulated the expression of Indoleamine 2,3-dioxygenase (IDO) via elevation of TGF-β. IDO inhibition led to a significant decrease in the expression of FOXP3 which is crucial for the induction of T regulatory cells. Thus, hCDR1 is potential candidate for the specific treatment of pSS patients
Beschreibung:Date Completed 01.07.2019
Date Revised 01.07.2019
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2018.05.001